Transcriptome analysis for differentiated gene expression analysis of TU2218, Vactosertib, and Ramucirumab on VEGF-induced endothelial cell anergy condition

Transcriptome analysis of HUVECs treated with TGFβRI or VEGFR2 inhibitors on endothelial cell anergy condition In this study, the dual inhibitory mechanism of TU2218 was identified using an in vitro analysis mimicking the tumor microenvironment and its anti-tumor effects were analyzed using in vivo mouse syngeneic tumor models. TU2218 directly normalized the activity of damaged T lymphocytes and natural killer cells from TGFβ and suppressed the activity and viability of regulatory T cells. The anergy of endothelial cells induced by VEGF stimulation was completely ameliorated by TU2218, an effect not observed with vactosertib, which only inhibits TGFβ signal. 18 RNA samples including triplicate-repeated samples for 6 conditions using the Affymetrix Human 2.0 ST platform. The data were summarized and normalized with robust multi-average (RMA) method implemented in Affymetrix® Power Tools (APT). We exported the result with gene level RMA analysis and performed the differentially expressed gene (DEG) analysis.